Liposomes versus Sphingosomes: Microfluidic DoE-Guided development of lipid nanocarriers for the delivery of a synthetic hMAO inhibitor.
Liposomes versus Sphingosomes: Microfluidic DoE-Guided development of lipid nanocarriers for the delivery of a synthetic hMAO inhibitor.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Rome, IT · Author affiliation
Department of Drug Chemistry and Technologies, "Sapienza" University of Rome, Rome, Italy. Electronic address: giorgio.buttitta@uniroma1.it.Location evidence
Latina, IT · Author affiliation
BSP Pharmaceuticals, Via Appia, km. 65, 561 04100 Latina LT, Italy.Location evidence
Chieti, IT · Author affiliation
Department of Innovative Technologies in Medicine & Dentistry, "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
Human monoamine oxidases (hMAO) are mitochondrial flavoenzymes responsible for the oxidative deamination of endogenous and exogenous amines, including key neurotransmitters. Their dysregulation has been associated with the onset and progression of neuropsychiatric and neurodegenerative disorders, such as depression and Parkinson's disease. Although pharmacological inhibition of hMAO represents a well-established therapeutic strategy, currently available inhibitors still present limitations, highlighting the need for both novel active compounds and advanced formulation approaches to improve their therapeutic performance. In this study, two lipid-based nanocarrier systems, namely phosphatidylcholine-based liposomes and sphingomyelin-based vesicles (sphingosomes), were developed for the delivery of BT12, a promising novel benzo[b]thiophene-derived hMAO inhibitor characterized by extremely low aqueous solubility. A microfluidic approach combined with a multi-step Design of Experiments (DoE) strategy was employed to design and optimize both formulations. In this context, the systematic DoE strategy enabled the identification of critical process parameters influencing key quality attributes, including particle size, polydispersity index, and theoretical encapsulation efficiency. The optimized formulations (size < 100 nm; PDI ≈ 0.2) exhibited comparable physicochemical and morphological properties, as well as good colloidal stability under refrigerated conditions and in biologically relevant media. While sphingosomes showed a comparatively higher theoretical encapsulation efficiency (35.8 ± 1.1%) compared to liposomes (20.4 ± 0.7%), in vitro release studies demonstrated controlled and sustained release profiles for both systems over 72 h, with sphingosomes displaying slower release kinetics. Biological evaluation on SH-SY5Y neuronal-like cells indicated that both formulations were well tolerated, with liposomes exhibiting slightly higher cytocompatibility. Confocal microscopy of fluorescently labeled nanoparticles confirmed efficient cellular association and/or uptake for both systems, with no evident differences between formulations. Overall, these findings highlight the role of lipid composition in modulating nanocarrier performance, revealing a balance between comparatively greater BT12 retention and cytocompatibility, and supporting the rational design of lipid-based delivery systems for poorly water-soluble hMAO inhibitors.